Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

  • Jiménez, Natalia|||0000-0002-7057-0426
  • Garcia de Herreros, Marta
  • Reig, Oscar|||0000-0003-1166-6943
  • Marín Aguilera, Mercedes
  • Aversa, Caterina
  • Ferrer-Mileo, Laura
  • García-Esteve, Samuel|||0000-0002-7680-2048
  • Rodríguez-Carunchio, Leonardo|||0000-0002-7019-554X
  • Trias, Isabel|||0000-0001-9841-4380
  • Font, Albert|||0000-0003-3908-1111
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Climent, Miguel Ángel|||0000-0001-7523-0212
  • Cros Costa, Sara|||0000-0001-8279-784X
  • Chirivella, Isabel|||0000-0002-0733-3276
  • Domènech, Montserrat|||0000-0003-3973-0986
  • Figols, Mariona
  • Carles, Joan|||0000-0002-9983-5934
  • Suárez, Cristina|||0000-0002-0502-5528
  • Herrero Rivera, Daniel
  • Gonzalez-Billalabeitia, Enrique|||0000-0003-3143-3143
  • Cívico, Claudia
  • Sala-González, Núria
  • Ruiz de Porras, Vicenç|||0000-0002-4352-1784
  • Ribal, María J.|||0000-0001-8142-5382
  • Prat, Aleix|||0000-0003-2377-540X
  • Mellado, Begoña|||0000-0002-8088-5966
BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients. DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter retrospective biomarker study in mHSPC patients. TSGlow status was defined when two or more out of the three TSGs presented low RNA expression by nCounter in formalin-fixed paraffin-embedded samples and TSGwt for the remaining cases. The microarray data from the CHAARTED trial were analyzed as an independent validation cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Molecular data were correlated with CRPC-free survival (CRPC-FS) and overall survival (OS) by the Kaplan-Meier method and multivariate Cox analysis. RESULTS AND LIMITATIONS: A total of 226 patients were included, of whom 218 were eligible: 93 were treated with ADT and 125 with ADT + D; 75.7% presented de novo stage IV and 67.9% high-volume disease. TSGlow (19.2%) was independently correlated with shorter CRPC-FS (hazard ratio [HR] 1.8, p = 0.002) and OS (HR 2, p = 0.002). In the CHAARTED trial, TSGlow was independently correlated with lower CRPC-FS (HR 2.2, p = 0.02); no differences in clinical outcomes according to treatment were observed in TSGlow patients, while a significant benefit was observed for ADT + D in the TSGwt group for CRPC-FS (HR 0.4, p < 0.001) and OS (HR 0.4, p = 0.001). However, no interaction was observed between TSG signature and treatment in either series. Study limitations are the retrospective design, small sample size, and lack of inclusion of patients treated with ADT + ART. CONCLUSIONS: TSGlow expression correlates with adverse outcomes in patients with mHSPC. The investigation of new therapeutic strategies in these patients is warranted. PATIENT SUMMARY: The low RNA expression of tumor suppressor genes in the tumors is correlated with adverse outcomes in patients with metastatic hormone-sensitive prostate cancer.